Who is sponsoring NCT00014092?

NCT00014092 is sponsored by Saint Francis Hospital.

What condition does NCT00014092 study?

NCT00014092 studies Melanoma (Skin).

What drugs are being tested in NCT00014092?

Interventions: aldesleukin, recombinant interferon alfa, sargramostim, temozolomide.

What is the status of NCT00014092?

NCT00014092 is currently COMPLETED.

Last reviewed 2013-03-25 · How we verify

Treatment of Patients With Metastatic Malignant Melanoma With Chemobiotherapy With Temozolomide, GM-CSF, IL2, and Interferon Alfa-2b Phase II Trial

NCT00014092 Phase 2 COMPLETED

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill cancer cells or may interfere with the growth of cancer cells. Combining chemotherapy with biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by sargramostim, interleukin-2, and interferon alfa in treating patients who have stage IV melanoma that cannot be treated with surgery.

Details

Lead sponsor	Saint Francis Hospital
Phase	Phase 2
Status	COMPLETED
Start date	1999-12
Completion	2003-12

Conditions

Melanoma (Skin)

Interventions

aldesleukin
recombinant interferon alfa
sargramostim
temozolomide

Countries

United States